IN8bio, a clinical-stage biopharmaceutical company, announced it will showcase new clinical data and advances in its gamma-delta (γδ) T cell engager platform at key medical conferences including ASCO 2026 and its own R&D Day on May 21. The presentations highlight progress in treating glioblastoma and autoimmune diseases using novel T cell therapies, with expert insights from leading neuro-oncologists. This series of events underscores IN8bio's commitment to developing innovative therapies addressing difficult-to-treat cancers and autoimmune conditions, with further details and materials to be shared post-conferences on their investor website.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
